Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

  1. Sousa, B.B.
  2. de Almeida, C.R.
  3. Barahona, A.F.
  4. Lopes, R.
  5. Martins-Logrado, A.
  6. Cavaco, M.
  7. Neves, V.
  8. Carvalho, L.A.R.
  9. Labaõ-Almeida, C.
  10. Coelho, A.R.
  11. Bento, M.L.
  12. Lopes, R.M.R.M.
  13. Oliveira, B.L.
  14. Castanho, M.A.R.B.
  15. Neumeister, P.
  16. Deutsch, A.
  17. Vladimer, G.I.
  18. Krall, N.
  19. Joaõ, C.
  20. Corzana, F.
  21. Seixas, J.D.
  22. Fior, R.
  23. Bernardes, G.J.L.
Aldizkaria:
ACS Pharmacology and Translational Science

ISSN: 2575-9108

Argitalpen urtea: 2022

Alea: 5

Zenbakia: 11

Orrialdeak: 1156-1168

Mota: Artikulua

DOI: 10.1021/ACSPTSCI.2C00163 GOOGLE SCHOLAR lock_openSarbide irekia editor
Gordailu instituzionala: lock_openSarbide irekia Editor

Garapen Iraunkorreko Helburuak